THE PRESENT INVENTION PROVIDES A MESOTHELIOMA THERAPEUTIC AGENT CONTAINING AN INTERLEUKIN-6 (IL-6) ANTAGONIST SUCH AS ANTIBODY TO IL-6 RECEPTOR (IL-6R), AND A MESOTHELIOMA CELL GROWTH INHIBITOR CONTAINING AN IL-6 ANTAGONIST SUCH AS ANTIBODY TO IL-6R.